Relationship of therapeutic cancer vaccine development to population disease burden and five-year survival

Human Vaccines

Volumn 7, Issue 11, 2011, Pages 1124-1129

  Dayoub, Elias J ^a   Davis, Matthew M ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Cancer; Clinical trials; Immunotherapy; Incidence; Mortality; Vaccine

Indexed keywords

CANCER VACCINE;

ARTICLE; BLADDER CANCER; BRAIN TUMOR; BREAST CANCER; CANCER IMMUNIZATION; CANCER INCIDENCE; CANCER MORTALITY; CANCER PREVENTION; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; DRUG EFFECT; DRUG EFFICACY; HODGKIN DISEASE; HUMAN; KIDNEY CANCER; LEUKEMIA; LUNG CANCER; MELANOMA; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PANCREAS CANCER; PROSTATE CANCER; SURVIVAL RATE; SURVIVAL TIME; UTERINE CERVIX CANCER;

EID: 81855189566     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.11.17837     Document Type: Article

References (11)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60:277-300; PMID:20610543; http://dx.doi.org/10.3322/caac.20073.
2. Vergati M, Intrivici C, Huen NY, Schlom J, Tsang KY. Strategies for cancer vaccine development. J Biomed Biotechnol 2010; 2010:596432; PMID:20706612; http://dx.doi.org/10.1155/2010/596432.
3. Aldrich JF, Lowe DB, Shearer MH, Winn RE, Jumper CA, Kennedy RC.Vaccines and immunotherapeutics for the treatment of malignant disease. Clin Dev Immunol. 2010; 2010:697158; PMID:20936120; http://dx.doi.org/10.1155/2010/697158.
4. Andersen MH, Junker N, Ellebaek E, Svane IM, Thor Straten P. Therapeutic cancer vaccines in combination with conventional therapies. J Biomed Biotechnol. 2010; 2010:237623; PMID:20617155; http://dx.doi.org/10.1155/2010/237623.
5. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, et al. IMPACT Study Investigators. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010; 363:411-22; PMID:20818862; http://dx.doi.org/10.1056/NEJMoa1001294.
6. Brower V. Approval of Provenge seen as first step for cancer treatment vaccines. J Natl Cancer Inst 2010; 102:1108-10; PMID:20668267; http://dx.doi.org/10.1093/jnci/djq295.
7. Davis MM, Dayoub EJ. A strategic approach to therapeutic cancer vaccines in the 21st century. JAMA 2011; 305:2343-4;; PMID:21642687; http://dx.doi.org/ 10.1001/jama.2011.814.
8. National Cancer Institute clinical trials database. http://www.cancer. gov/clinicaltrials/search. Accessed February 27, 2011.
9. National Cancer Institute. Cancer vaccine fact sheet. http://www.cancer.gov/cancertopics/factsheet/Therapy/cancer-vaccines. Accessed February 27, 2011.
10. U.S. National Institutes of Health. ClinicalTrials. gov. http://www.clinicaltrials.gov. Accessed February 27, 2011.
11. Davis MM, Butchart AT, Coleman MS, Singer DC, Wheeler JRC, Pok A, et al. The expanding vaccine development pipeline, 1995-2008. Vaccine 2010; 28:1353-6; PMID:19932670; http://dx.doi.org/10.1016/j.vaccine.2009.11.007.